MCID: VST006
MIFTS: 25

Vestibulocochlear Nerve Disease

Categories: Ear diseases, Neuronal diseases

Aliases & Classifications for Vestibulocochlear Nerve Disease

MalaCards integrated aliases for Vestibulocochlear Nerve Disease:

Name: Vestibulocochlear Nerve Disease 12 15
Vestibulocochlear Nerve Diseases 44 73
Cochlear Nerve Diseases 73
Acoustic Nerve Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12657
ICD10 33 H93.3 H93.3X
ICD9CM 35 388.5
MeSH 44 D000160
NCIt 50 C27207
SNOMED-CT 68 77949003

Summaries for Vestibulocochlear Nerve Disease

MalaCards based summary : Vestibulocochlear Nerve Disease, also known as vestibulocochlear nerve diseases, is related to vestibular neuronitis, and has symptoms including tinnitus and earache. An important gene associated with Vestibulocochlear Nerve Disease is RTEL1 (Regulator Of Telomere Elongation Helicase 1). The drugs Prednisolone and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include brain, and related phenotypes are Synthetic lethal with vaccinia virus (VACV) infection and embryo

Wikipedia : 76 The vestibulocochlear nerve (auditory vestibular nerve), known as the eighth cranial nerve, transmits... more...

Related Diseases for Vestibulocochlear Nerve Disease

Diseases related to Vestibulocochlear Nerve Disease via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 vestibular neuronitis 8.8 CACNA1A LMX1A PIR RTEL1 SALL1 SLC9C1

Symptoms & Phenotypes for Vestibulocochlear Nerve Disease

UMLS symptoms related to Vestibulocochlear Nerve Disease:


tinnitus, earache

GenomeRNAi Phenotypes related to Vestibulocochlear Nerve Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with vaccinia virus (VACV) infection GR00362-A 8.8 CACNA1A PIR SALL1

MGI Mouse Phenotypes related to Vestibulocochlear Nerve Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.55 LMX1A PIR RTEL1 SALL1 TCOF1
2 growth/size/body region MP:0005378 9.43 CACNA1A LMX1A PIR RTEL1 SALL1 TCOF1
3 nervous system MP:0003631 9.02 CACNA1A LMX1A RTEL1 SALL1 TCOF1

Drugs & Therapeutics for Vestibulocochlear Nerve Disease

Drugs for Vestibulocochlear Nerve Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
2
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
3
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3 302-25-0
4
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3 2921-57-5
5
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
6
Prednisolone hemisuccinate Experimental Phase 4,Phase 3 2920-86-7
7 Gentamicins Phase 4,Not Applicable
8 Anti-Bacterial Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
9 Anti-Infective Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Hormone Antagonists Phase 4,Phase 3,Phase 2
11 Antiemetics Phase 4,Phase 3
12 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Not Applicable
13 Neuroprotective Agents Phase 4,Phase 3
14 Prednisolone acetate Phase 4,Phase 3
15 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
16 Hormones Phase 4,Phase 3,Phase 2
17 glucocorticoids Phase 4,Phase 3,Phase 2
18 Autonomic Agents Phase 4,Phase 3
19 Gastrointestinal Agents Phase 4,Phase 3,Not Applicable
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
21 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
22 Protective Agents Phase 4,Phase 3
23 Methylprednisolone acetate Phase 4,Phase 3
24 Betamethasone Valerate Phase 4 2152-44-5
25 Anti-Asthmatic Agents Phase 4,Phase 3
26 Betamethasone benzoate Phase 4
27 Betamethasone sodium phosphate Phase 4
28 Respiratory System Agents Phase 4,Phase 3
29 Betamethasone-17,21-dipropionate Phase 4
30 Ophthalmic Solutions Phase 4
31
Ethanol Approved Phase 3 64-17-5 702
32
Cilostazol Approved, Investigational Phase 3 73963-72-1 2754
33
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 3 303-98-0 5281915
34 Ginkgo Phase 3
35 Complement System Proteins Phase 3
36 Trace Elements Phase 3
37 Micronutrients Phase 3
38 Vitamins Phase 3
39 Ubiquinone Phase 3
40 Lecithin Phase 3
41 Platelet Aggregation Inhibitors Phase 3,Phase 2
42 Fibrinolytic Agents Phase 3,Phase 2
43 Bronchodilator Agents Phase 3
44 Phosphodiesterase Inhibitors Phase 3
45 Vasodilator Agents Phase 3
46 Phosphodiesterase 3 Inhibitors Phase 3
47
Everolimus Approved Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
48
Sirolimus Approved, Investigational Phase 2,Phase 1,Early Phase 1 53123-88-9 46835353 6436030 5284616
49
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
50
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865

Interventional clinical trials:

(show top 50) (show all 87)
# Name Status NCT ID Phase Drugs
1 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Unknown status NCT02379754 Phase 4 Gentamicins
2 Acute Unilateral Vestibulopathy and Corticosteroid Treatment Recruiting NCT02912182 Phase 4 Betamethasone;Placebo;Prednisolone
3 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
4 Cacicol20® in Corneal Wound Healing and Nerve Regeneration After Phototherapeutic Keratectomy Terminated NCT02373397 Phase 4
5 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
6 The Efficacy of Steroid Therapy in Vestibular Neuritis Completed NCT02098330 Phase 3 Ginkgo biloba & Methylprednisolone;Ginkgo biloba
7 Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10 Completed NCT02333305 Phase 3
8 Cyberknife Radiosurgery for Patients With Neurinomas Recruiting NCT02055859 Phase 3
9 Effect of Renexin Tablet in Patients With Recurrent Vestibulopathy Terminated NCT01895400 Phase 3 Renexin (cilostazol 100mg + gingko biloba extract 80 mg);Placebo
10 Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Completed NCT01490476 Phase 2 RAD001
11 Complementary/Alternative Medicine for Abnormality in the Vestibular (Balance) System Completed NCT00032383 Phase 1, Phase 2
12 Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT02104323 Phase 2 Endostatin
13 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
14 Prednisone Treatment for Vestibular Neuronitis Completed NCT00271791 Phase 2 Prednisone;Prednisone
15 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
16 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT00973739 Phase 2 Lapatinib
17 Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 Completed NCT00004437 Phase 2
18 RGD PET/MRI in Sporadic Vestibular Schwannoma Recruiting NCT03393689 Phase 2 One injection of 68Ga-NODAGA-E[c(RGDyK)]2
19 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
20 Study of Aspirin in Patients With Vestibular Schwannoma Recruiting NCT03079999 Phase 2 Aspirin;Placebo
21 Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Recruiting NCT02934256 Phase 2 Icotinib
22 Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Recruiting NCT02129647 Phase 2 Axitinib
23 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Recruiting NCT01199978 Phase 2
24 AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas Active, not recruiting NCT02831257 Phase 2 AZD2014
25 Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT01767792 Phase 2 Bevacizumab
26 Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma Active, not recruiting NCT01345136 Phase 2 RAD001, everolimus
27 Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas Active, not recruiting NCT01125046 Phase 2
28 A Study of Nilotinib in Growing Vestibular Schwannomas Terminated NCT01201538 Phase 2 Nilotinib
29 PTC299 for Treatment of Neurofibromatosis Type 2 Terminated NCT00911248 Phase 2 PTC299
30 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
31 An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors Completed NCT00030043 Phase 1
32 Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Recruiting NCT01552434 Phase 1 Temsirolimus;Valproic Acid
33 Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma Suspended NCT01083966 Phase 1 Bevacizumab (Avastin)
34 Characterisation of Cortical Vestibular Evoked Potentials (C-VEPs) Unknown status NCT02463695 Not Applicable
35 The Role of Corticosteroids and Vestibular Exercises in Recovery of Vestibular Neuritis Unknown status NCT01231009 Early Phase 1 Corticosteroids
36 Effect of Implant Position on Magnetic Resonance Image Distortion Unknown status NCT02246231 Not Applicable
37 Vestibular Schwannoma and Psychological Factors Unknown status NCT01743248
38 Vestibular System in Migrainous Vertigo Patients Unknown status NCT00901953
39 NF2 Natural History Consortium Unknown status NCT00004483
40 Longitudinal Study Of The Evoked Compound Action Potential Measured In Children Cochlear Implant Users Completed NCT00725998
41 Optimizing the Ocular Surface Prior to Cataract Surgery Completed NCT02766907 Not Applicable
42 Vestibular Evaluation After Vestibular Schwannoma Treatment Completed NCT03670589
43 Role of Psychiatric Profile in Prehabituated Patients After Vestibular Schwannoma Surgery Completed NCT03638310 Not Applicable
44 Reliability of Functional Outcome Measures in Neurofibromatosis 2 Completed NCT03617276
45 WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data Completed NCT03210285
46 Vertigo Perception and Quality of Life in Patients After Surgical Treatment of Vestibular Schwannoma Completed NCT02963896 Not Applicable gentamicin
47 Home-based Computer Gaming in Vestibular Rehabilitation Completed NCT01943955 Not Applicable
48 Resiliency Training for Patients With NF2 Via Videoconferencing With Skype Completed NCT02811718 Not Applicable
49 Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach Completed NCT02309099 Not Applicable
50 Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype Completed NCT02298270 Not Applicable

Search NIH Clinical Center for Vestibulocochlear Nerve Disease

Cochrane evidence based reviews: vestibulocochlear nerve diseases

Genetic Tests for Vestibulocochlear Nerve Disease

Anatomical Context for Vestibulocochlear Nerve Disease

MalaCards organs/tissues related to Vestibulocochlear Nerve Disease:

41
Brain

Publications for Vestibulocochlear Nerve Disease

Articles related to Vestibulocochlear Nerve Disease:

# Title Authors Year
1
Facial and vestibulocochlear nerve disease in six horses. ( 6643213 )
1983

Variations for Vestibulocochlear Nerve Disease

Expression for Vestibulocochlear Nerve Disease

Search GEO for disease gene expression data for Vestibulocochlear Nerve Disease.

Pathways for Vestibulocochlear Nerve Disease

GO Terms for Vestibulocochlear Nerve Disease

Biological processes related to Vestibulocochlear Nerve Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 central nervous system neuron differentiation GO:0021953 8.62 CACNA1A LMX1A

Molecular functions related to Vestibulocochlear Nerve Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ion channel activity GO:0005216 8.62 CACNA1A SLC9C1

Sources for Vestibulocochlear Nerve Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....